Epirubicin-loaded nanomedicines beat immune checkpoint blockade resistance in glioblastoma

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.